🧬 Clinical Trials Database

Pre-post study evaluating the safety and efficacy of ibogaine-magnesium therapy in 30 Special Operations veterans with sequelae of repeated blast exposure. Primary results published in Nature Medicine (2024, PMID 38182784).

Phase 1/2a study of oral ibogaine: a single-ascending-dose stage in healthy volunteers to determine the maximum tolerated or treat-to-target dose, followed by a randomized, double-blind, placebo-controlled proof-of-concept stage in opioid withdrawal. Completed January 2024 per the registry.

Phase 2 study of ibogaine to support detoxification from long-term methadone maintenance, run at Hospital Universitari Sant Joan in Reus, Spain. Completed April 2024 per the registry.

Open-label escalating-dose Phase 2 trial of ibogaine for alcohol dependence at the University of São Paulo. Completed October 2024 per the registry.

Observational neuroimaging study of how ibogaine treatment changes brain activity and symptoms in moderate-to-severe opioid use disorder; participants are people already planning ibogaine treatment independently. Recruiting as of October 2026 per the registry.

Observational study evaluating the impact of ibogaine-magnesium, 5-MeO-DMT, magnetic e-resonance therapy, and physiological supplementation on PTSD and TBI-related cognitive symptoms among Special Operations Forces veterans.

Single-site Phase 1/2a three-cohort study of medically supervised ibogaine versus extended-release naltrexone, with 12 months of recovery support, in adults with moderate-to-severe opioid use disorder. Registry start date July 2027; not yet recruiting.

Phase 2 study of hormone replacement, magnetic e-resonance therapy, ibogaine and 5-MeO-DMT in Special Operations Forces veterans, sponsored at Johns Hopkins and withdrawn before enrolling participants. Listed for completeness — withdrawn registrations are part of the honest research picture.